Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters
Cancer Drug Resistance · 12.01.2026
DOI: 10.20517/cdr.2025.151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Drug Resistance, online erschienen am 12.01.2026. Verfasst von Jacob S Roth und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Antibody-drug conjugates (ADCs) feature an antibody recognizing a specific protein joined to a potent toxic payload. Numerous ADCs have received U.S. Food and Drug Administration (FDA) approval; however, clinical resistance arises. Resistance mechanisms include decreased expression or mutation of the antibody target, impaired payload release, or increased expression of adenosine triphosphate (ATP)-binding cassette (ABC) efflux transporters associated with multidrug resistance. We therefore sought to characterize the interactions of ABC multidrug transporters with ADC payloads.
Methods
We performed a high-throughput screen with 27 common ADC payloads using cell lines expressing ABC transporters P-glycoprotein [P-gp, encoded by ABC subfamily B member 1 (ABCB1)] or ABC subfamily B member G2 (ABCG2, encoded by ABCG2). Confirmatory assays were also performed using cells transfected to express P-gp, ABCG2, or multidrug resistance-associated protein 1 (MRP1, encoded by ABCC1).
Results
Several commonly used ADC payloads were substrates of P-gp, including calicheamicin γ1, monomethyl auristatin E, mertansine (DM1), and ravtansine (DM4). All the pyrrolobenzodiazepines tested - SJG136, SGD-1882, SG2057, and SG3199 - were substrates of P-gp, ABCG2, and MRP1. The modified anthracyclines nemorubicin and its metabolite PNU-159682 were poorly transported by both ABCB1 and ABCG2 and displayed nanomolar to picomolar toxicity. Further, we found that the efficacy of the FDA-approved ADC mirvetuximab soravtansine, with DM4 as the toxic payload, was decreased in cell lines expressing P-gp. In contrast, Duocarmycin DM and PNU-159682 were exquisitely toxic to a panel of 99 cancer cell lines of varying origins.
Conclusion
Several commonly used ADC payloads can be transported by ABC transporters, potentially leading to transporter-mediated drug resistance in patients. Future ADCs should be developed using payloads that are not ABC transporter substrates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
- Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Zitieren
APA
Roth, J. S., Guo, H., Chen, L., Shen, M., Gbadegesin, O., Robey, R. W., Gottesman, M. M., & Hall, M. D. (2026). Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.151
Vancouver
Roth JS, Guo H, Chen L, Shen M, Gbadegesin O, Robey RW, et al. Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters. Cancer Drug Resistance. 2026. doi:10.20517/cdr.2025.151
BibTeX
@article{Roth2026,
author = {Roth, Jacob S and Guo, Hui and Chen, Lu and Shen, Min and Gbadegesin, Omotola and Robey, Robert W and Gottesman, Michael M and Hall, Matthew D},
title = {Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters},
journal = {Cancer Drug Resistance},
year = {2026},
doi = {10.20517/cdr.2025.151}
}
EUVIMED